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Abstract
Background: China has an aging population with an increasing number of adults aged ≥ 60 years. Influenza causes
a heavy disease burden in older adults, but can be alleviated by vaccination. We assessed the cost-effectiveness of a
potential government-funded seasonal influenza vaccination program in older adults in China.
Methods: We characterized the health and economic impact of a fully funded influenza vaccination program for
older adults using China-specific influenza disease burden, and related cost data, etc. Using a decision tree model,
we calculated the incremental costs per quality-adjusted life year (QALY) gained of vaccination from the societal
perspective, at a willingness-to-pay threshold equivalent to GDP per capita (US$8840). Moreover, we estimated the
threshold vaccination costs, under which the fully funded vaccination program is cost-effective using GDP per
capita as the willingness-to-pay threshold.
Results: Compared to current self-paid vaccination, a fully funded vaccination program is expected to prevent 19,
812 (95% uncertainty interval, 7150–35,783) influenza-like-illness outpatient consultations per year, 9418 (3386–17,
068) severe acute respiratory infection hospitalizations per year, and 8800 (5300–11,667) respiratory excess deaths
due to influenza per year, and gain 70,212 (42,106–93,635) QALYs per year. Nationally, the incremental costs per
QALY gained of the vaccination program is US$4832 (3460–8307), with a 98% probability of being cost-effective.
The threshold vaccination cost is US$10.19 (6.08–13.65). However, variations exist between geographical regions,
with Northeast and Central China having lower probabilities of cost-effectiveness.
Conclusions: Our results support the implementation of a government fully funded older adult vaccination program
in China. The regional analysis provides results across settings that may be relevant to other countries with similar
disease burden and economic status, especially for low- and middle-income countries where such analysis is limited.
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Background
Seasonal influenza is a major cause of mortality, with re-
cent estimates suggesting that 291,000–646,000 influenza-
associated respiratory deaths occur globally each year [1].
Older adults are at increased risk of hospitalization or
death if infected and thus are included in the recom-
mended groups for annual influenza vaccination by the
World Health Organization (WHO) [2]. The World
Health Assembly set a target of attaining vaccination
coverage of 75% in this group by 2010 [3]. Most high-
income countries and many upper middle-income coun-
tries, like Thailand and Brazil, have incorporated seasonal
influenza vaccination for older adults into their National
Immunization Program, which has significantly increased
vaccination uptake [4–6].
As the world’s most populous country, China has more
adults ≥ 60 years (> 210 million in 2016) than any other
country, accounting for nearly a quarter of the global total.
China is also aging rapidly; adults ≥ 60 years account for
15% of the population in 2016 [7] and will increase to 26%
by 2030 [8]. Influenza caused 66–105 severe acute respira-
tory infection (SARI) hospitalizations per 100,000 adults ≥
60 years in China [9, 10]. Annually, over 80% of influenza-
related excess deaths occurred in older adults [11, 12], with
an average excess respiratory mortality rate per season esti-
mated at 38.5 (95% confidence interval, 95%CI 36.8–40.2)
per 100,000 persons between 2010 and 2015 [12]. However,
there is no nationwide government-funded influenza vac-
cination program for older adults in China, and the cost of
vaccination is completely borne by individuals. This self-
paid vaccination system contributes to an extremely low
vaccine uptake of 4% in this age group, far behind the tar-
get of 75% [13]. Only a handful of relatively wealthy cities
provide free influenza vaccination for older adults paid by
local governments [14]. For example, since 2007, Beijing
has provided free influenza vaccination to older adults,
leading to the uptake reaching 39% in 2012 [15].
Following a health scare involving improper refrigeration
of transported vaccines sold privately nationwide in 2016
[16], the State Council of China recommended acceleration
of the inclusion into the National Immunization Program
of vaccines currently sold in the private sector [17]. The
new vaccine administration law in 2019 requires establish-
ing a “national dynamic adjustment mechanism” for inclu-
sion/exclusion of vaccines into National Immunization
Program [18]. Both the State Council and National
Immunization Advisory Committee also recommended
taking into consideration the cost-effectiveness of vaccin-
ation alongside traditional considerations of vaccine effi-
cacy and safety for vaccine policy-making [18].
A systematic review of cost-effectiveness studies of in-
fluenza vaccination showed that globally a third of stud-
ies (8/27) found vaccination in older adults to be cost-
saving, and most of the remainder found vaccination to
be cost-effective [19]. However, to date no comprehen-
sive study has been conducted in mainland China, where
the economic impact of fully funded vaccination pro-
grams may differ greatly across regions due to large vari-
ations in influenza seasonality, disease burden,
demographic structure, and social economic develop-
ment [11, 20, 21]. Hence, the objective of this study is to
answer the question of whether a fully funded influenza
vaccination program for nearly a quarter of the world’s
older adult population is an efficient use of resources in
mainland China, and to further explore whether varia-
tions in this result exist across geographical regions.
Methods
Following WHO guidance on the economic evaluation of
influenza vaccination [22], we performed a cost-
effectiveness analysis of a government-funded influenza
vaccination program for adults ≥ 60 years compared to the
status quo of vaccinees paying out-of-pocket (hereafter
“fully funded vaccination program” and “self-paid vaccin-
ation program” respectively) from the societal perspectives.
As most costs and effects due to influenza occur during a
single influenza season, we used a time horizon of 1 year,
with the exception of tracking all the years of life lost when
a patient died of influenza-related causes.
Decision tree model
We developed a static decision tree model (Fig. 1) to cal-
culate the per person costs of vaccination, per person costs
due to influenza, and per person health utility loss due to
influenza. From these estimates, we estimated the impact
of the fully funded program compared to self-paid vaccin-
ation on health and economic outcomes at the regional
and national level. We then used these outcomes to calcu-
late the incremental cost-effectiveness of the fully funded
program. Detailed methods are shown in Additional file 1.
As current vaccine coverage is only 4% and is concen-
trated in a few highly developed cities with local govern-
ment funding [13], we assumed the probability of being
vaccinated was zero under the status quo. There is sig-
nificant uncertainty in the vaccine uptake that may be
achieved in a potential fully funded vaccination program.
The experience of Beijing showed that the uptake in
older adults increased substantially from 2% in 1999 to
39% in 2012 [15, 23] after fully funded influenza vaccin-
ation was offered in 2007. It is likely that the uptake in
other less densely populated and developed provinces
would not increase as quickly as Beijing, the capital of
China, where residents likely to have greater access to
health care facilities. We therefore used a conservative
coverage assumption of 30% in the analysis.
An older adult is assumed to have a risk of acquiring a
symptomatic influenza infection annually. Someone with
symptomatic influenza then has a probability of seeking
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medical treatment, including self-medication, seeking
healthcare in a community or township health service
center, consulting a doctor in an outpatient department,
or being hospitalized. Each infected person also has a
probability of dying of influenza-related causes, whether
or not the person has received healthcare.
The models were stratified by area (rural/urban) and
geographical regions (Additional file 2: Figure S1: North-
ern, Northeast, Northwest, Eastern, Central, Southwest,
and Southern). All analyses were performed in R version
3.5.0 (https://www.r-project.org).
Data sources
Population
The model tracked older adults aged 60–64, 65–69, 70–
74, 75–79, and ≥ 80 years. The age-specific population
size in 2016 was obtained from the National Bureau of
Statistics in China and stratified by area (rural/urban)
using the proportion of older persons living in urban
areas reported in the 2010 Population Census of China
[24] (Additional file 3: Table S1).
Older adults were further split into high- and low-risk
groups. High-risk individuals are defined as those with an
increased risk of hospitalization or death if infected by
influenza due to underlying medical conditions as listed in
the WHO influenza vaccine guidelines, including chronic
obstructive pulmonary disease, asthma, diabetes, and
chronic cardiac disease [25] The remaining population was
categorized as low risk. The probability of an older adult
having at least one underlying medical disease was esti-
mated from the results of the China Health and Retirement
Longitudinal Study [26, 27], a nationally representative
study on health status in older people (Additional file 4:
Figures S2–S3).
Influenza-related disease burden
Influenza-like-illness (ILI) consultations due to influenza
The yearly average risk of ILI-related primary care or out-
patient consultations due to influenza in China was esti-
mated to be 0.9 per 1000 (95% CI 0.4–1.5) between 2010
and 2015 [28]. The influenza-related ILI consultation risk
Fig. 1 Decision tree model for influenza vaccination in older adults. Chance node 2 is the same as chance node 1, and chance node 4 is the
same as chance node 3
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varied significantly cross provinces (Additional file 5:
Table S2), ranging from 10 to 690 per 100,000.
Hospitalization
It was found that influenza was associated with an esti-
mated 89 (95%CI 85–90) SARI hospitalizations per 100,
000 for individuals ≥ 65 years during 2011–2012 in Jingz-
hou (a city in Southern China) [9]. The rates were 105
(95%CI 85–129) and 66 (95%CI 50–86) per 100,000
people in Beijing (a province in Northern China) during
the 2014–2015 and 2015–2016 seasons, respectively
[10]. In our study, the influenza-related hospitalization
rates in other Southern and Northern provinces (Add-
itional file 2: Figure S1) were estimated using the local
influenza-related ILI consultation rate multiplied by the
ratio of influenza-related SARI hospitalization rate to
influenza-related ILI consultation rate separately in
Jingzhou and Beijing [9, 10, 28].
Mortality
The national average influenza-associated excess mortality
attributable to respiratory diseases was estimated to be
38.5 (95%CI 36.8–40.2) per 100,000 between 2010 and
2015 in China [12]. Variation (19.0–83.2/100,000) was ob-
served across provinces (Additional file 5: Table S2).
We found a clear positive relationship between Gross
Regional Product per capita and influenza-related ILI
consultation risk (Pearson correlation coefficient = 0.83,
p < 0.05). This variation is likely to be explained by dif-
ferences in health care access or under-reporting. In the
base case analysis, we used original influenza-related ILI
consultation and excess mortality rates as reported for
each province in the literatures [12, 28]. This assumes
that the differences between provinces are genuine and
are explained by differences in influenza epidemiology.
The highest influenza-related ILI consultation risk oc-
curs in Shanghai (690/100,000), a high-income province
with very good health care access and surveillance sys-
tem. Accordingly, in the scenario analyses, we assumed
every province has the same risk as Shanghai based on
the “under-reporting” hypothesis or assumed the differ-
ences are explained by differences in health care access
(i.e., “health care access” hypothesis).
For excess mortality, we assumed every province has
the same risk as the province with the highest risk,
which is 83.2/100,000 in Gansu province [12]. A total of
four scenario analyses were performed in this study, with
detailed descriptions shown in Table 1.
A systematic review demonstrated that the presence of
“any risk factor” (using the WHO risk factors definition
[25]) was associated with an increased risk of hospital admis-
sion (odds ratio 3.39, 95%CI 2.60–4.42) and death (odds ra-
tio 2.04, 95%CI 1.74–2.39) in influenza-related patients [29].
Healthcare seeking behavior
A household survey on health seeking behavior of adult
patients with acute respiratory infections carried out in
China during 11/2009–03/2010, found that (1) in urban
areas, 9.7% of acute respiratory infection cases did not
seek any medical help, 66.0% self-medicated, or visited a
doctor in community or township health centers, and the
remaining 24.3% visited a doctor in county or higher-level
hospitals; (2) in rural areas, the relevant proportions were
respectively 8.6%, 79.0%, and 12.4% [30]. We assumed that
influenza patients have the same healthcare-seeking
behaviors as acute respiratory infections cases.
Influenza-related costs
We used the average drug cost per outpatient in township
healthcare centers (US$ 5.4 in 2017) and that in commu-
nity healthcare centers (US$11.9 in 2017) as a proxy of the
cost for self-medication of influenza patients in urban and
rural areas, respectively [31]. We previously found the
treatment costs for influenza-related outpatients and inpa-
tients aged 60 years old and over were respectively US$129
(95% uncertainty interval, 95%UI 75–156) and US$2735
(1401-4482) in East China in 2013 [32]. The costs were ex-
trapolated to other regions in China in proportion to the
regional GDP (gross domestic product) per capita.
We also considered the lost productivity due to prema-
ture mortality attributable to influenza, which was esti-
mated using the friction cost method. The length of the
friction period was assumed to be 3 months, the elasticity
of labor time versus production assumed to be 0.8, and
the costs of filling a vacancy and training new personnel
estimated to be US$357 in 2009 [33, 34]. The yearly in-
come per capita of older adults (urban US$3896; rural
US$1241) was obtained from the fourth survey of the liv-
ing conditions of older adults in urban/rural China in
2014 [35]. The labor force participation rates of older
adults were derived from the 2010 Population Census of
China [24]. All costs were adjusted and converted to US
dollars in 2017 using the consumer price index and the
exchange rate of 1 US$ = 6.75 CNY [36].
Quality-adjusted life years (QALYs) lost
The number of QALYs lost due to influenza was calcu-
lated as the sum of QALYs lost due to non-fatal episodes
plus life years lost due to fatal episodes. The duration of
non-fatal episodes was assumed to be respectively 6.2 days
(standard deviation, 2.2) and 16.0 days (10.7) for
influenza-related outpatients and inpatients. Their associ-
ated health utility was separately estimated to be 0.5733
(95%UI 0.4650–0.6608) and 0.4128 (0.1793–0.6380) [37].
The background health utility (urban 0.7719–0.8071; rural
0.6943–0.7434) was obtained from the China Health and
Retirement Longitudinal Study [38].
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Life years lost due to fatal episodes were estimated
based on risk-, area-, and age-specific life expectancy.
Life expectancy was calculated using the life table ap-
proach and mortality data in 2017 from China Health
and Family Planning Statistical Yearbook [31, 39]. Life
years lost were discounted at an annual rate of 3% [40]
(Additional file 6: Tables S3–S4).
Vaccine effectiveness and cost
Unlike the US Flu Vaccine Effectiveness network [41],
there is no regular evaluation of influenza vaccine effect-
iveness in mainland China. Even though a few studies
have been conducted to try to evaluate the local influenza
vaccine effectiveness in the older adults in the Capital city
Beijing during 2013–2016 [42, 43], the estimates were not
precise due to limited sample size, and it cannot represent
the effectiveness across China due to large variations in
terms of seasonality and activity of influenza virus [20].
A recent meta-analysis of test-negative design case-
control studies conducted between 2004 and 2013 indi-
cated that influenza vaccine is effective against
laboratory-confirmed influenza (odds ratio 0.48; 95% CI
0.39–0.59) in older adults when the vaccine strains
closely match the circulating influenza viruses, and also
had significant effectiveness when vaccine is poorly
matched (odds ratio 0.64; 95% CI 0.52–0.78) [44]. We
conservatively used the efficacy of poorly matched vac-
cines in the baseline analysis. Adverse effects associated
with influenza vaccination which were not considered as
serious adverse events are extremely rare [45].
The procurement cost of influenza vaccination (not in-
cluding vaccine logistic and administration costs) in 2013
was US$5.73 per dose (95%UI 5.43–6.03) for the 0.50ml
formulation trivalent inactivated influenza vaccine [14].
Socioeconomic status
Luo and Xie [46] found that 74.5% of older adults were
economically independent (i.e., their daily expenses could
be paid by their retirement wage/pension or other in-
come) in China. They also found older adults with eco-
nomic independence had 26.4% lower risk of respiratory
diseases mortality. Hence, we further calculated the bene-
fits and cost-effectiveness of vaccination by economic
independence.
Outcome measures
In this study, we calculated the incremental costs per
QALY gained of vaccination and evaluated the health and
economic impact of fully funded influenza vaccination at
the national and seven regional levels, respectively. Because
China does not have an official threshold for cost-
effectiveness, we used a willingness-to-pay threshold of the
GDP per capita (US$8840 in 2017) in the base case analysis,
and a more stringent threshold of US$3780–US$5880 per
QALY gained proposed by University of York economists
[47] to construct cost-effectiveness acceptability curves
(CEAC). Due to the unavailability of vaccine logistic and
administration costs, only vaccine procurement costs were
included in the base case and sensitivity analyses. We fur-
ther performed analyses for threshold vaccination costs
(TVC), below which fully funded vaccination program
would be considered cost-effective.
Sensitivity analysis
We performed probabilistic sensitivity analyses to explore
the influence of all parameters on incremental cost-
effectiveness ratios (ICERs). This was done using Monte
Carlo sampling with applicable distributions for different
parameters (Table 2), drawing 10,000 samples, then calcu-
lating the median, and 95% UIs for the ICERs based on
the 2.5th and 97.5th percentiles of the 10,000 simulations.
Scenario sensitivity analyses were also conducted (1) from
the health system perspective (only considering the direct
medical costs for influenza patients), (2) using well-
matched vaccine effectiveness [44], (3) using a discount
rate of zero for QALYs loss as recommended by WHO
Table 1 Description of base case and scenario analyses
Analyses Influenza-related ILI consultation [28] Influenza-associated excess mortality attributable to respiratory diseases
[12]
Base case Used original rate as reported for each province in the literature Used original rate as reported for each province in the literature
Scenario 1 Used original rate as reported for each province in the literature,
and assumed the difference between any other province and
Shanghai is due to difference in health care access (i.e., “health
care access” hypothesis)
Assumed every province has the same risk as Gansu Province,
with the highest rate of 83.2/100,000
Scenario 2 Assumed every province has the same risk as Shanghai, with
the highest rate of 690/100,000
Assumed every province has the same risk as Gansu Province,
with the highest rate of 83.2/100,000
Scenario 3 Used original rate as reported for each province in the literature,
and assumed the difference between any other province and
Shanghai is due to difference in health care access (i.e., “health
care access” hypothesis)
Used original rate as reported for each province in the literature
Scenario 4 Assumed every province has the same risk as Shanghai, with
the highest rate of 690/100,000
Used original rate as reported for each province in the literature
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guidelines [48], and (4) considering the circulating influ-
enza virus strains change after 2009 H1N1 pandemic, the
most recent vaccine effectiveness between 2013 and 2018
in the USA (range 12–50%) [49] were used in the sensitiv-
ity analysis in order to evaluate its impact on our out-
comes, with the vaccine effectiveness of 12% and 50%
separately for mismatched and well-matched vaccines.
Results
Impact and cost-effectiveness in the base case scenario
At the national level, a total of 63.4 million older adults in
China are expected to be vaccinated annually. Vaccination
is expected to prevent 19,812 (95%UI 7150–35,783)
influenza-related ILI outpatient consultations per year,
9418 (3386–17,068) influenza-related SARI hospitalizations
per year, and 8800 (5300–11,667) influenza-related deaths
due to respiratory diseases per year, with separately 40%,
69%, and 57% occurring in high-risk groups (Fig. 2 and
Additional file 7: Figure S4).
The fully funded vaccination program is estimated to
cost US$ 339 (310–363) million, but gain 70,212 (42,106-
93,635) QALYs, 98% of which were due to influenza-
related excess deaths averted (Fig. 2). A total of 38% of the
increment cost and 54% of incremental QALYs occur in
high-risk groups (Additional file 7: Figure S4). The QALYs
gained by vaccination were 3 per 10,000 persons at an in-
cremental cost of US$16,111 per 10,000 persons in older
adults with economic independence and 4 per 10,000 per-
sons at an incremental cost of US$15,763 per 10,000 per-
sons in older adults without economic independence.
Table 2 Key model parameter distributions
Parameter Mean (range/standard deviation)* Distribution
Proportion of high-risk groups Additional file 4: Fig. S3 Beta
Flu-related ILI consultation rate [28] Additional file 5: Table S2 Normal
Flu-related SARI hospitalization (per 100,000) [9]
Beijing (2013–2014) 105 (95%CI 85–129) Normal with μ = 105, sd = 11.22
Beijing (2014–2015) 66 (95%CI 50–86) Normal with μ = 66, sd = 9.18
Jingzhou, Hubei province (2011–2012) 89 (95%CI 85–90) Uniform (min = 85/100,000, max = 90/100,000)
Flu-related respiratory excess mortality [12] Additional file 5: Table S2 Lognormal
Healthcare-seeking behavior (%) [30]
Probability of no-healthcare-use Urban 9.7, Urban: Dirichlet with α1 = 107, α2 = 704, α3 = 269,
Rural: Dirichlet with α1 = 43, α2 = 394, α3 = 62
Rural 8.6
Probability of self-treatment, seeking care in
Community/Township Health Service Centers
Urban 66.0,
Rural 79.0
Probability of visiting doctors in county-level
and above hospitals
Urban 24.3
Rural 12.4
Odds ratio of influenza-related hospitalization in
high-risk groups compared to low-risk groups [29]
3.39 Lognormal with μ = 1.22, sd = 0.14
Odds ratio of influenza-related death in high-risk
groups compared to low-risk groups [29]
2.04 Lognormal with μ = 0.71, sd = 0.08
Vaccine cost (US$ in 2013) [14] 5.73 (95%UI 5.43–6.03) Bootstrap from data on influenza vaccine cost
Influenza outpatients visits and hospitalization
costs (US$ in 2013) [32]
Outpatients: 129 (95%UI 75–156) Bootstrap from data on national retrospective survey
Inpatients: 2735 (95%UI 1401–4482)
Duration of influenza episode for outpatients and
inpatients (days) [37]
Outpatients: 6.2 (SD 2.2) Bootstrap from data on national retrospective survey
Inpatients: 16.0 (SD 10.7)
Utility of influenza outpatients and inpatients [37] Outpatients: 0.5733 (95%UI 0.4650–0.6608) Bootstrap from data on national retrospective survey
Inpatients: 0.4128 (95%UI 0.1793–0.6380)
Background health utility [38] Urban
60–74 years: 0.8071 (SD 0.0039);
≥ 75 years: 0.7719 (SD 0.0093)
Rural
60–74 years: 0.7434 (SD 0.0031);
≥ 75 years: 0.6943 (SD 0.0078)
Normal distribution
Risk of infected from influenza in vaccinated group
vs. unvaccinated group (odds ratio) [44]
0.64 (0.52–0.78) Lognormal with μ = − 0.45, sd = 0.10
*Used in one-way sensitivity analysis. 95%CI denotes 95% confidence interval; 95%UI denotes 95% uncertainty interval calculated by bootstrap methods
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Using the GDP per capita as a threshold, the fully funded
vaccination in older adults in China is cost-effective with
an ICER of US$4832 (3460-8307) per QALY gained. The
TVC is US$10.19 (6.08–13.65), under which the fully
funded vaccination program is cost-effective using GDP
per capita as the willingness-to-pay threshold (Fig. 3).
Substantial variations in health and economic outcomes
are observed across regions (Fig. 2). Except in Northeast
China (US$8945), the median ICER (US$2691–7115) is
below the GDP per capita and hence cost-effective. The
TVC in Northeast and Central China is lower than the
national average, decreasing to US$5.66 (3.41–7.70) and
US$7.06 (4.15–9.66) (Fig. 3).
Probabilistic sensitivity analyses
At the national level, 98% of Monte Carlo samples are
considered cost-effective under base case assumptions
with a threshold of GDP per capita. However, significant
differences are observed for regions. For Northeast and
Central China, the proportion respectively reduces to 48%
and 82%. While for other regions, the probability is over
96% (Fig. 4). Using a much more stringent threshold of
US$3780–5880 per QALY gained [47], the probability of
cost-effective for vaccination decreases to 9–80% at the
national level. Similar patterns are observed across regions
(Fig. 5). At the national level, the probability of cost-
effectiveness of vaccination was 99% in high-risk groups
and 86% in low-risk groups (Additional file 7: Figure S5);
97% for older adults with economic independence, and
99% for those without economic independence.
Scenario analyses
Compared to the base case scenario, the influenza-related
excess mortality due to respiratory diseases increased 1–3
folds in Central, Northeast, and Southwest China, while
only 47–86% for other regions in scenarios 1 and 2. The
low probability of being cost-effective (around 48%) is only
observed for Northeast China in base case and scenario 2
(Fig. 4). Compared to the base case scenario, TVC
increases by 55–330% in scenarios 1 and 2, and 4–24% in
scenario 4, while decreases slightly in scenario 3 (Fig. 3).
Compared to the base case scenario, for scenarios 1
and 2, the probabilities of being cost-effective are much
higher; they are over 80% across regions even using a
much more stringent threshold of US$3780 per QALY
gained [47], and all are 100% using a willingness-to-pay
threshold of GDP per capita. Similar patterns as the base
case are observed for scenarios 3 and 4 (Fig. 5).
Compared to the societal perspective analysis above, ICERs
increase slightly (mostly by < 10% depending on region and
scenario) from a healthcare provider perspective (Add-
itional file 8: Figures S6–S8). Vaccine effectiveness and dis-
count rate have a high impact on ICERs. When the vaccine is
well-matched circulating influenza strains, the fully funded
vaccination program is 100% cost-effective across all regions
(Additional file 9: Figures S9–S11). When the discount rate
for QALYs loss is zero, the fully funded vaccination program
is cost-effective across all regions, at a probability of > 90% ex-
cept for Northern China in base case and scenario 3 (around
80%) (Additional file 10: Figures S12–S14).
Compared to the base case analysis (with a mis-
matched vaccine and a discount rate of 3%) from the
Fig. 2 a–f Epidemiological and economic impact of fully funded influenza vaccination program in older adults, stratified by geographic regions, China
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societal perspective, the TVC decreases by less than 5%
from the healthcare provider perspective, while it in-
creases by 44–45% when vaccine strains match the cir-
culating strains, and increases by 18–21% when discount
rate is zero for QALYs loss (Fig. 3).
Compared to using a vaccine effectiveness of 36% in the
baseline analysis [44], using an vaccine effectiveness of 12%
in USA (mismatched) [49] resulted in a decrease of around
67% in terms of national influenza-related ILI consultations,
hospitalizations, and deaths averted and QALYs gained sep-
arately, while an increase of 5% in incremental costs, lead-
ing to median ICER (US$ 15,190) beyond GDP per capita
for base case scenario. The probability of being cost-
effective for scenarios 1 and 2 remained at 99–100%. Using
a vaccine effectiveness of 50% in the USA (matched) [49],
national influenza-related ILI consultations, hospitaliza-
tions, and deaths averted and QALYs gained increased by
39–44%, while incremental cost decreased by 1–9%, leading
to 100% probability of being cost-effective for all scenarios
(details shown in the Additional file 11: Table S5). Similar
patterns are observed across geographic regions.
Discussion
The provision and management of vaccines in China is
currently undergoing regulatory reforms [16, 50]. Expand-
ing China’s government-funded vaccination programs is
now recommended by both WHO and the State Council
of China [17, 51]. In 2019, the influenza vaccine was one
Fig. 3 a–d Threshold vaccination costs (TVC)
Fig. 4 Monte Carlo simulation results on the cost-effectiveness for fully funded vaccination program compared to self-paid vaccination program
(gray line denotes China’s GDP per capita in 2017 and circle denotes the 95%UI)
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of the vaccines that went through comprehensive evalu-
ation by the National Immunization Advisory Committee
of China for inclusion into the National Immunization
Program as a fully government-funded vaccine. A first
step towards this could be considering vaccination for
older adults due to their higher risk of influenza-related
hospitalization and mortality. Our analysis comprehen-
sively evaluates the health and economic impact of a po-
tential fully funded influenza vaccination program in older
adults. It shows that vaccinating older adults in China is
cost-effective, with an ICER of US$ 4832 per QALY
gained (lower than GDP per capita), despite conservative
assumptions about vaccine effectiveness assumed in the
base case scenario. However, we find that variations in
health and economic impact exist across regions.
In our study, the fully funded vaccination program could
reduce both QALY loss and productivity loss due to pre-
mature deaths. While productivity loss only contributes to
< 2% of the decrease in total costs, the relevant QALY loss
averted contributes to > 96% in total QALYs saved. Ac-
cordingly, variation in influenza-related respiratory excess
mortality across regions is a significant factor for different
ICERs observed here (base case vs. scenarios 1 and 2). Our
analysis demonstrates that in the base case analysis, the
probability of being cost-effective for the fully funded influ-
enza vaccination program is much lower in regions with
lower reported mortality burden than that with heavy in-
fluenza excess mortality burden (e.g., lower in Northeast
compared to. Northern China) [12]. The influenza mortal-
ity in Northeast China may genuinely be lower due to
lower population density and reduced air pollution. On the
other hand, it may simply appear lower due to factors such
as patients seeking advanced healthcare in neighboring de-
veloped regions [12] and poor quality of influenza and
death surveillance. Since the two sets of potential reasons
for lower mortality are difficult to disentangle, we should
be very cautious in interpreting regional-level economic re-
sults. This highlights the importance of improved influenza
surveillance, particularly in less developed regions of China,
in order to better target influenza control programs. Varia-
tions in influenza-related ILI consultation only have slightly
impact on the ICERs (base case vs. scenario 4).
In Northeast China, the fully funded influenza vaccination
program is considered cost-effective if TVC is respectively
below US$5.7 in the base case analysis. We used the private
sector vaccine cost in the model, which is US$5.73 per dose
currently [14], much higher than most of the vaccines cur-
rently used in the National Immunization Program [52].
Fig. 5 Cost-effectiveness acceptability curve (US$3780 and US$5880 denote the willingness-to-pay thresholds calculated by Ochalek [46], while
US$8840 is the GDP per capita in 2017, China)
Yang et al. BMC Medicine           (2020) 18:90 Page 9 of 12
Several Chinese manufactures produce influenza vaccines in
Northeast China [45]. A government-funded influenza vac-
cination program using local manufacturers’ vaccines is
likely to have lower delivery costs due to economies of scale
and lower procurement costs due to increased consumer
bargaining power. That will certainly increase the likelihood
that the fully funded influenza vaccination is cost-effective
in this region.
Only two studies to date has assessed the cost-
effectiveness of influenza vaccination among older adults in
China [53, 54]. The study of Chen et al. [53] had a number
of limitations: (i) it used influenza-related outpatient and
hospitalization rates in the USA, which may not be good
proxies for relevant rates in China due to the different in-
fluenza seasonality, virus activity, health-seeking behavior,
etc. [20] And (ii) it used influenza-related mortality before
2009 influenza pandemic in China, even though the burden
has changed due to the displacement of seasonal A(H1N1)
virus after pandemic [11, 12]. With these shortcomings, the
paper suggested that government-funded influenza vaccin-
ation was < 50% likely to be cost-effective, when compared
to a threshold of one times GDP per capita. Similarly, the
second study used the influenza-related burden in a few de-
veloped cities like Beijing and Shanghai [54]. In our study,
we used the most recent China-specific post-2009 pan-
demic data stratified by provinces, including influenza-
related outpatient, hospitalization, and mortality rates.
The number of excess respiratory deaths [28] used in
this study may not fully capture all influenza-associated
deaths because influenza virus infections not only cause
respiratory deaths, but also deaths from other diseases
such as cardiovascular diseases, diabetes, and renal dis-
eases [11]. Accordingly, vaccination could be even more
cost-effective than presented here.
In our analysis, we used the same vaccine effectiveness
against laboratory-confirmed influenza-related consult-
ation, hospitalization, and death. Castilla et al. conducted
a test-negative case-control study in Spain during six in-
fluenza seasons, to compare the vaccine effectiveness in
preventing laboratory-confirmed influenza in outpatient
and inpatient cases at the same time and in the same
population of older adults. They concluded that no dif-
ference was observed in vaccine effectiveness in general
practice and hospital settings [55]. If a higher VE against
hospitalizations and deaths was used in our study by as-
suming influenza vaccine mitigates influenza illness se-
verity, the probability of vaccination being cost-effective
would increase due to more treatment costs and prod-
uctivity losses averted and more QALYs gained.
It is known that influenza burden and vaccine effective-
ness vary across years partly due to predominant circulating
viruses and how closely related the viruses in the vaccine
are to the circulating viruses. Previously studies have dem-
onstrated that more influenza-related consultations and
greater excess mortality were observed in 2014–2015 sea-
son when influenza A(H3N2) virus predominated [28], and
the effectiveness of influenza vaccines was reduced due to
an antigenic mismatch between the circulating strain and
vaccine virus [42]. In this case, vaccination is likely to be
less cost-effective than in other years. However, in our
study, we conducted the cost-effectiveness analysis using
the average influenza burden after 2009 H1N1 pandemic
and vaccine effectiveness across several years regardless of
influenza type/subtype/lineage. This is because our work is
intended to inform the decision to introduce influenza vac-
cination into the National Immunization Programme for
the long term, rather than for a specific season or against a
specific type/subtype/lineage.
A limitation of our study is that the influenza-related
SARI hospitalization rate is only available in one city each in
Southern and Northern China [9, 10]. These two cities may
not fully represent the hospitalization rate across China. We
used the ratio of the influenza-related SARI hospitalization
rate to influenza-related ILI consultation rate separately in
Jingzhou, Hubei, and Beijing as a multiplier to estimate the
influenza-related SARI hospitalization rate for the rest of
Southern and Northern China, respectively. However, it
may not be a good proxy due to different health seeking be-
haviors especially between areas with varying levels of socio-
economic development, and health service provision.
China’s first vaccine administration law allows provincial
governments to add additional vaccines into their local fully
funded vaccine list on the basis of local disease burden [18].
Until now, only a few highly developed provincial- and
prefecture-level cities have offered fully funded influenza
vaccination for older adults (e.g., Beijing and Shenzhen).
These local initiatives have achieved remarkable increases
in local vaccine uptake [14, 15]. However, expanding
such fully funded vaccination to the entire population or
even large regions of China would require large
budget allocations. Because of that, there is a need for de-
tailed cost-effectiveness analysis to determine if such a
move is good value for money. Hence, our results fill a key
evidence gap needed by decision-makers in China. Due to
large apparent variations in influenza disease burden, and
socioeconomic development level across regions, our re-
gional analyses could also provide information on the cost-
effectiveness of fully funded influenza vaccination that may
be relevant to other countries with similar disease burden
and economic status, especially low- and middle-income
countries where cost-effectiveness analysis is limited [19].
Conclusions
Making use of the China-specific influenza disease burden,
including influenza-related outpatient consultations, severe
acute respiratory infection hospitalizations and respiratory
excess deaths, as well as related cost data, we built up a de-
cision tree model to characterize the cost-effectiveness of
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introducing influenza vaccination for older adults. Our re-
sults support the implementation of a government fully
funded older adult vaccination program in China. The re-
gional analysis provides results across settings that may be
relevant to other low- and middle-income countries with
similar disease burden and economic status.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12916-020-01545-6.
Additional file 1: Methods of estimating the impact of vaccination
program at the population level.
Additional file 2: Figure S1. Map showing geographical regions in
mainland China.
Additional file 3: Table S1. Population size.
Additional file 4: Figure S2. Schematic diagram for estimating high-
risk population size; Figure S3. Probability of having underlying diseases.
Additional file 5: Table S2. Influenza-related disease burden.
Additional file 6: Table S3. Age-specific mortality by rural/urban areas;
Table S4. Life expectancy.
Additional file 7: Figure S4. Epidemiological and economic impact by
regions and risk groups; Figure S5. Monte Carlo simulation results by
regions and risk groups.
Additional file 8: Figure S6. Epidemiological and economic impact
(analyses from the health system perspective); Figure S7. Monte Carlo
simulation results (analyses from the health system perspective); Figure
S8. CEAC (analyses from the health system perspective).
Additional file 9: Figure S9. Epidemiological and economic impact
(analyses with well-matched vaccines); Figure S10. Monte Carlo simula-
tion results (analyses with well-matched vaccines); Figure S11. CEAC
(analyses with well-matched vaccines).
Additional file 10: Figure S12. Epidemiological and economic impact
(analyses with a discount rate of zero for QALYs loss); Figure S13. Monte
Carlo simulation results (analyses with a discount rate of zero for QALYs
loss); Figure S14. CEAC (analyses with a discount rate of zero for QALYs
loss).
Additional file 11: Table S5. Comparison of baseline analysis with that
using US vaccine effectiveness.
Abbreviations
95%CI: 95% Confidence interval; 95%UI: 95% Uncertainty interval; CEAC: Cost-
effectiveness acceptability curves; GDP: Gross domestic product;
ICER: Incremental cost-effectiveness ratios; ILI: Influenza-like-illness;
QALYs: Quality-adjusted life years; SARI: Severe acute respiratory infections;
TVC: Threshold vaccination costs; WHO: World Health Organization
Acknowledgements
Not applicable.
Authors’ contributions
HY and MJ designed the study. JY, LF, PW, HY, EHYL, JTW, YL, and BJC
collected the data. JY, KEA, and MB developed the model. JY analyzed the
data. JY, HY, and MJ wrote the drafts of the manuscript and interpreted the
findings. All authors commented on and revised drafts of the manuscript. All
authors read and approved the final report.
Funding
This study was funded by the National Science Fund for Distinguished
Young Scholars (grant no. 81525023), the National Natural Science
Foundation of China (grant no. 81903373), the National Science and
Technology Major Project of China (grant no. 2017ZX10103009–005), and the
National Institute for Health Research (NIHR) (grant no. 16/137/109) using UK
aid from the UK Government to support global health research. The views
expressed in this publication are those of the author(s) and not necessarily
those of the NIHR or the UK Department of Health and Social Care.
Availability of data and materials
The data generating the findings of this article are included within the article
and its additional files.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
YH has received funding from Sanofi Pasteur, GlaxoSmithKline, bioMérieux
Diagnostic Product (Shanghai), Yichang HEC Changjiang Pharmaceutical Company
and Shanghai Roche Pharmaceuticals Company. BJC received honoraria from
Sanofi Pasteur and Roche for consulting on influenza treatment and prevention.
The rest of the authors declare that they have no competing interests.
Author details
1School of Public Health, Fudan University, Key Laboratory of Public Health
Safety, Ministry of Education, Shanghai, China. 2Centre for Mathematical
Modelling of Infectious Diseases, London School of Hygiene and Tropical
Medicine, London, UK. 3Department of Infectious Disease Epidemiology,
London School of Hygiene & Tropical Medicine, London, UK. 4Centre for
Global Health Research, Usher Institute of Population Health Sciences and
Informatics, The University of Edinburgh, Edinburgh, UK. 5Key Laboratory of
Surveillance and Early-warning on Infectious Disease, Division of Infectious
Disease, Chinese Center for Disease Control and Prevention, Beijing, China.
6MRC Centre for Global Infectious Disease Analysis, School of Public Health,
Imperial College London, London, UK. 7WHO Collaborating Centre for
Infectious Disease Epidemiology and Control, School of Public Health, Li Ka
Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special
Administrative Region, China. 8Modelling and Economics Unit, Public Health
England, London, UK.
Received: 4 December 2019 Accepted: 3 March 2020
References
1. Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, Cohen C,
Gran JM, Schanzer D, Cowling BJ, et al. Estimates of global seasonal influenza-
associated respiratory mortality: a modelling study. Lancet. 2018;391(10127):1285–300.
2. World Health Organiztion. Vaccines against influenza WHO position paper-
November 2012. Wkly Epidemiol Rec. 2012;87(47):461–76.
3. Fifty-sixth World Health Assembly resolution WHA56.19. Prevention and
control of influenza pandemics and annual epidemics. 28 May 2003. http://
www.who.int/immunization/sage/1_WHA56_19_Prevention_and_control_
of_influenza_pandemics.pdf. Accessed 25 Sept 2015.
4. European Centre for Disease Prevention and Control. Seasonal influenza
vaccination and antiviral use in EU/EEA Member States: Overview of
vaccination recommendations for 2017–2018 and vaccination coverage rates
for 2015–2016 and 2016–2017 influenza seasons. Available from: https://ecdc.
europa.eu/sites/portal/files/documents/Seasonal-influenza-antiviral-use-EU-EEA-
Member-States-December-2018_0.pdf. Accessed 8 Feb 2019.
5. Bof de Andrade F, Sayuri Sato AP, Moura RF, Ferreira Antunes JL. Correlates
of influenza vaccine uptake among community-dwelling older adults in
Brazil. Human Vaccines Immunotherapeutics. 2017;13(1):103–10.
6. Owusu JT, Prapasiri P, Ditsungnoen D, Leetongin G, Yoocharoen P, Rattanayot
J, Olsen SJ, Muangchana C. Seasonal influenza vaccine coverage among high-
risk populations in Thailand, 2010-2012. Vaccine. 2015;33(5):742–7.
7. United Nations. World population. https://population.un.org/wpp/
Download/Standard/CSV/. Accesed 3 Apr 2019.
8. United Nations. World population ageing 2015. http://www.un.org/en/
development/desa/population/publications/pdf/ageing/WPA2015_Report.
pdf. Accessed 16 Mar 2016.
9. Yu H, Huang J, Huai Y, Guan X, Klena J, Liu S, Peng Y, Yang H, Luo J, Zheng
J, et al. The substantial hospitalization burden of influenza in Central China:
surveillance for severe, acute respiratory infection, and influenza viruses,
2010-2012. Influenza Other Respir Viruses. 2014;8(1):53–65.
Yang et al. BMC Medicine           (2020) 18:90 Page 11 of 12
10. Zhang Y, Muscatello DJ, Wang Q, Yang P, Pan Y, Huo D, Liu Z, Zhao X, Tang Y, Li
C, et al. Hospitalizations for influenza-associated severe acute respiratory infection,
Beijing, China, 2014–2016. Emerging Infectious Disease. 2018;24(11):2098–102.
11. Yu H, Feng L, Viboud CG, Shay DK, Jiang Y, Zhou H, Zhou M, Xu Z, Hu N, Yang
W, et al. Regional variation in mortality impact of the 2009 A(H1N1) influenza
pandemic in China. Influenza Other Respir Viruses. 2013;7(6):1350–60.
12. Li L, Liu Y, Wu P, Peng Z, Wang X, Chen T, Wong JYT, Yang J, Bond HS,
Wang L, et al. Influenza-associated excess respiratory mortality in China,
2010-15: a population-based study. Lancet Public Health. 2019;4(9):e473–81.
13. Zhou L, Su Q, Xu Z, Feng A, Jin H, Wang S, Feng Z. Seasonal influenza
vaccination coverage rate of target groups in selected cities and provinces
in China by season (2009/10 to 2011/12). PLoS One. 2013;8(9):e73724.
14. Yang J, Atkins KE, Feng L, Pang M, Zheng Y, Liu X, Cowling BJ, Yu H. Seasonal
influenza vaccination in China: landscape of diverse regional reimbursement
policy, and budget impact analysis. Vaccine. 2016;34(47):5724–35.
15. Lv M, Fang R, Wu J, Pang X, Deng Y, Lei T, Xie Z. The free vaccination policy of
influenza in Beijing, China: the vaccine coverage and its associated factors.
Vaccine. 2016;34(18):2135–40.
16. Parry J. Crackdown on illegal vaccine sales in China leads to 37 arrests. BMJ.
2016;352:i1750.
17. Decision of the State Council on amending Regulations on Management of
Vaccine Circulation and Inoculation (Order No. 668 of the State Council of
the People’s Republic of China). http://www.gov.cn/zhengce/content/2016-
04/25/content_5067597.htm>. Accessed 17 May 2016.
18. The State Council of the People's Republic of China. http://www.gov.cn/
xinwen/2019-06/30/content_5404540.htm. Accessed 30 June 2019.
19. Peasah SK, Azziz-Baumgartner E, Breese J, Meltzer MI, Widdowson MA. Influenza
cost and cost-effectiveness studies globally--a review. Vaccine. 2013;31(46):5339–48.
20. Yu H, Alonso WJ, Feng L, Tan Y, Shu Y, Yang W, Viboud C. Characterization of regional
influenza seasonality patterns in China and implications for vaccination strategies:
spatio-temporal modeling of surveillance data. PLoS Med. 2013;10(11):e1001552.
21. Feng L, Shay DK, Jiang Y, Zhou H, Chen X, Zheng Y, Jiang L, Zhang Q, Lin H,
Wang S, et al. Influenza-associated mortality in temperate and subtropical
Chinese cities, 2003-2008. Bull World Health Organ. 2012;90(4):279–288B.
22. World Health Organization. Guidance on the economic evaluation of influenza
vaccination. http://www.who.int/immunization/research/development/
influenza_maternal_immunization/en/index2.html. Accessed 5 July 2018.
23. Wu J, Dong ZY, Ding LX, Liu HL. Influenza vaccination practice in Beijing
during 1999~2004. J of pub health and Prev Med. 2005;16(4):19–21.
24. Population Census Office under the State Council & Department of Population
and Employment Statistics National Bureau of Statistics of China: Tabulation on
the 2010 Population Census of the People’s Republic of China. http://www.
stats.gov.cn/tjsj/pcsj/rkpc/6rp/indexch.htm. Accessed 12 Jan 2015. In..
25. World Health Organization. WHO interim global epidemiological
surveillance standards for influenza (July 2012). http://www.who.int/
influenza/resources/documents/INFSURVMANUAL.pdf. Accessed 4 May 2014.
26. China Health and Retirement Longitudinal Study. http://charls.ccer.edu.cn/
en. Acceseed 20 Nov 2015.
27. Zhao Y, Hu Y, Smith JP, Strauss J, Yang G. Cohort profile: the China Health and
retirement longitudinal study (CHARLS). Int J Epidemiol. 2014;43(1):61–8.
28. Feng L, Feng S, Chen T, Yang J, Lau Y, Peng Z, Li L, Wang X, Wong J, Qin Y,
et al. Burden of influenza associated outpatient consultations in China, 2006-
2015: a population-based study. Influenza Other Respir Viruses. 2019;00:1–11.
29. Mertz D, Kim TH, Johnstone J, Lam PP, Science M, Kuster SP, Fadel SA, Tran D,
Fernandez E, Bhatnagar N, et al. Populations at risk for severe or complicated
influenza illness: systematic review and meta-analysis. BMJ. 2013;347:f5061.
30. Gao LX. Survey on the knowledge, attitudes, practices of the public during
the pandemic of a/H1N1 2009 (dissertation) (in Chinese). 2011.
31. National Health and Family Planning Commission of China: China Health
and Family Planning Statistical Yearbook 2018. Chinese Academy of Medical
Sciences & Peking Union Medical College Press. Beijing, 2018.
32. Yang J, Jit M, Leung KS, Zheng YM, Feng LZ, Wang LP, Lau EH, Wu JT, Yu H.
The economic burden of influenza-associated outpatient visits and
hospitalizations in China: a retrospective survey. Infect Dis Poverty. 2015;4:44.
33. Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction
cost method for measuring indirect costs of disease. J Health Econ. 1995;
14(2):171–89.
34. Zhu JL, Mao XM. Research on calculation and analysis of recruitment cost in
a tertiary hospital. Chinese Hospitals. 2012;16(12):63–5.
35. China National Committee on Ageing. The fourth sampling survey on the
living conditions of the elderly in urban and rural China. http://www.
cncaprc.gov.cn/contents/2/177118.html. Accessed 3 Dec 2018.
36. National Bureau of Statistics of China. Consumer Price Index http://data.
stats.gov.cn/english/easyquery.htm?cn=C01. Accessed 2 Jan 2016.
37. Yang J, Jit M, Zheng Y, Feng L, Liu X, Wu JT, Yu H. The impact of influenza
on the health related quality of life in China: an EQ-5D survey. BMC Infect
Dis. 2017;17(1):686.
38. You X, Zhang Y, Zeng J, Wang C, Sun H, Ma Q, Ma Y, Xu Y. Disparity of the
Chinese elderly's health-related quality of life between urban and rural
areas: a mediation analysis. BMJ Open. 2019;9(1):e024080.
39. World Health Organization. WHO methods for life expectancy and healthy
life expectancy. http://www.who.int/healthinfo/statistics/LT_method.pdf?ua=
1&ua=1. Accessed 2 Jan 2016.
40. World Health Organization. Making choices in health: WHO guide to cost-
effectiveness analysis. In. Edited by Tan-Torres Edejer T BR, Adam T,
Hutubessy T, Acharya A, Evans DB, Murray CJL.; 2003.
41. US Centers for Disease Control and Prevention. US Flu VE Network. https://
www.cdc.gov/flu/vaccines-work/us-flu-ve-network.htm. Accessed 8 Feb 2020.
42. Qin Y, Zhang Y, Wu P, Feng S, Zheng J, Yang P, Pan Y, Wang Q, Feng L,
Pang X, et al. Influenza vaccine effectiveness in preventing hospitalization
among Beijing residents in China, 2013–15. Vaccine. 2016;34(20):2329–33.
43. Zhang Y, Wu P, Feng L, Yang P, Pan Y, Feng S, Qin Y, Zheng J, Puig-Barbera
J, Muscatello D, et al. Influenza vaccine effectiveness against influenza-
associated hospitalization in 2015/16 season, Beijing, China. Vaccine. 2017;
35(23):3129–34.
44. Darvishian M, Bijlsma MJ, Hak E, van den Heuvel ER. Effectiveness of
seasonal influenza vaccine in community-dwelling elderly people: a meta-
analysis of test-negative design case-control studies. Lancet Infect Dis. 2014;
14(12):1228–39.
45. Chinese Center for Disease Control and Prevention. Guideline on seasonal
influenza vaccination during the 2018–2019 season in China (in Chinese).
http://www.chinacdc.cn/jkzt/crb/bl/lxxgm/jszl_2251/201809/t20180921_194
050.html. Accessed 12 Oct 2018.
46. Luo W, Xie Y. Socioeconomic disparities in mortality among Chinese elderly.
Popul Stud (Camb). 2014;68(3):305–20.
47. Ochalek J, Lomas J, Claxton K. Estimating health opportunity costs in low-
income and middle-income countries: a novel approach and evidence from
cross-country data. BMJ Glob Health. 2018;3(6):e000964.
48. WHO guide for standardization of economic evaluations of immunization
programmes, 2nd edition. Geneva: World Health Organization; 2019.
Licence: CC BY-NC-SA 3.0 IGO. https://www.who.int/immunization/
documents/who_ivb_19.10/en/. Accessed 8 Feb 2020.
49. US Centers for Disease Control and Prevention. Past Seasons Vaccine
Effectiveness Estimates. https://www.cdc.gov/flu/vaccinfluenza cases in older
adults, northern Spain, 2010/11 to 2015ines-work/past-seasons-estimates.
html. Accessed 8 Feb 2020.
50. Zhou M, Qu S, Zhao L, Kong N, Campy KS, Wang S. Trust collapse caused by
the Changsheng vaccine crisis in China. Vaccine. 2019;37(26):3419–25.
51. Chinadaily: WHO says list of free vaccines should be expanded. http://africa.
chinadaily.com.cn/china/2016-03/30/content_24171305.htm. Accessed 17
May 2016.
52. Zheng Y, Rodewald L, Yang J, Qin Y, Pang M, Feng L, Yu H. The landscape
of vaccines in China: history, classification, supply, and price. BMC Infect Dis.
2018;18(1):502.
53. Chen C, Liu GE, Wang MJ, Gao TF, Jia HP, Yang H, Feng LZ. Cost-effective
analysis of seasonal influenza vaccine in elderly Chinese population. Chin J
Prev Med. 2019;53(10):993–9.
54. Jiang M, Li P, Wang W, Zhao M, Atif N, Zhu S, Fang Y. Cost-effectiveness of
quadrivalent versus trivalent influenza vaccine for elderly population in
China. Vaccine. 2020;38(5):1057–64.
55. Castilla J, Martínez-Baz I, Navascués A, Casado I, Aguinaga A, Díaz-González
J, Delfrade J, Guevara M, Ezpeleta C. Primary Health Care Sentinel Network
Of Navarre, Network For Influenza Surveillance In Hospitals Of Navarre.
Comparison of influenza vaccine effectiveness in preventing outpatient and
inpatient influenza cases in older adults, northern Spain, 2010/11 to 2015/
16. Euro Surveill. 2018;23(2):16-00780.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Yang et al. BMC Medicine           (2020) 18:90 Page 12 of 12
